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Abstract
Background: Numerous stroke studies have controversially shown estrogens to be either neuroprotective or
neurodamaging. The discordant results observed in rat brain ischemia models may be a consequence of
discrepancies in estrogen administration modes resulting in plasma concentration profiles far from those intended.
To test this hypothesis we reproduced in detail and extended an earlier study from our lab using a different mode
of 17b-estradiol administration; home-made silastic capsules instead of commercial slow-release 17b-estradiol
pellets. Four groups of female rats (n = 12) were ovariectomized and administered 17b-estradiol or placebo via
silastic capsules. All animals underwent MCAo fourteen days after ovariectomy and were sacrificed three days later.
Results: In contrast to our earlier results using the commercial pellets, the group receiving 17b-estradiol during the
entire experiment had significantly smaller lesions than the group receiving placebo (mean ± SEM: 3.85 ± 0.70%
versus 7.15 ± 0.27% of total slice area, respectively; p = 0.015). No significant neuroprotection was found when the
17b-estradiol was administered only during the two weeks before or the three days immediately after MCAo.
Conclusions: The results indicate that different estrogen treatment regimens result in diametrically different effects
on cerebral ischemia. Thus the effects of estrogens on ischemic damage seem to be concentration-related, with a
biphasic, or even more complex, dose-response relation. These findings have implications for the design of animal
experiments and also have a bearing on the estrogen doses used for peri-menopausal hormone replacement
therapy.
Background
During recent years substantial research efforts have
been allocated to investigating the potential beneficial
effects of estrogens on stroke incidence and mortality.
The hypothesis that estrogens may have neuroprotective
properties evolved from the observation that premeno-
pausal women have lower risk of stroke than men of the
same age have, and that stroke incidence amongst
women increases in menopause [1-3]. Estrogens are
widely administered as peri-menopausal hormone repla-
cement therapy (HRT), and several large studies on
human populations have been devoted to investigating
the relationship between HRT and stroke. Of these,
some have shown neuroprotection [4,5], while others
have cast this effect of estrogens and HRT in doubt
[6-9]. The largest, the Women’s Health Initiative (WHI),
including more than 16,000 women, was interrupted
prematurely because of findings of an increased risk of
coronary heart disease, breast cancer and stroke [9].
The fact that the WHI study was discontinued because
of HRT-related health risks strongly reduces the possibility
of performing further similar studies in human popula-
tions concerning HRT and stroke. This currently leaves us
with the use of animal models to elucidate the effects of
estrogens in stroke. Therefore the importance of animal
studies has increased, and even more since they are sine
qua non for investigating the detailed biological mechan-
isms of estrogens. Several studies have been performed on
the question of estrogens and ischemic brain damage in
animal models, rat being most commonly used. As in the
human population studies the results of animal studies
have been varying. Although a majority of studies have
shown neuroprotective effects of estrogens [10-15], some
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have also shown increased damage after stroke in estro-
gen-supplemented animals [16-20], among these a study
from our laboratory [21]. In a recent review we hypothe-
sized that the divergent results were a consequence of dif-
ferences in doses of estrogens delivered by different
administration modes, commercial pellets being the only
method resulting in increased lesions [22]. To test this
hypothesis we designed an experiment that exactly
mimicked an earlier experiment from our lab, except for
the mode of administrating 17b-estradiol, the most potent
of naturally occurring estrogens [21]. Silastic capsules
filled with 17b-estradiol in oil were chosen since they have
been shown to produce the most physiologically relevant
17b-estradiol serum levels, in contrast to the earlier used
slow-release pellets from Innovative Research of America
(IRA), which have been shown to produce early, very high
hormone peaks [23,24]. However, the slow-release pellets
are available for several doses and release-periods, and our
conclusions are obviously limited to the pellets tested.
Also, although the 17b-estradiol levels produced by the
silastic capsules can be seen as more physiological, even
this hormone profile is artificial because of its lack of nat-
ural cyclic variation. Having earlier shown neurodamage
in altogether 22 rats receiving supraphysiological doses of
17b-estradiol [21], we considered it more innovative to
study when 17b-estradiol has its potential effect on cere-
bral ischemia by adding two groups receiving the hormone
only before or only after the MCAo, respectively, rather
than to include high-dose estradiol groups by means of
slow release pellets or silastic capsules.
Methods
Animals
Forty-eight female Sprague Dawley rats were obtained
from B&K Universal (Sollentuna, Sweden). The rats
were kept at constant room temperature (21°C) with
12-h light/dark and sound (soft radio music) cycles for
at least one week prior to the experiment. At the start
of the experiment the rats were 12-14 weeks of age and
weighed 270 ± 3 g (mean ± SEM). The animals were
housed 2-4 in each cage, with food (Lactamin, Vadstena,
Sweden) and water provided ad libitum. The cages were
20 cm high and had a floor area of 59.5 × 38.0 cm. All
procedures were conducted in accordance with the
National Committee for Animal Research in Sweden
and Principles of Laboratory Animal Care (NIH publica-
tion no. 86-23, revised 1985). The study was approved
by the Local Ethics Committee for Animal Care and
Use at Linköping University. The animals used in this
experiment were also included in a study of neuropep-
tide levels in the brain.
Ovariectomy and 17b-estradiol administration
Experimental groups
Before experimental procedures, the rats were randomly
allocated into four groups (n = 12 per group). All animals
were anesthetized with 1.2-1.4% (4.2% for induction) iso-
flurane (Forene, Abbott, Scandinavia AB, Kista, Sweden)
in an oxygen/nitrous oxide mixture (30%/70%) and ovar-
iectomized via the dorsal route on day 0 of the experi-
ment. One group of rats (Gr.P/P) concurrently received
placebo capsules, which were substituted with new pla-
cebo capsules at the time of middle cerebral artery occlu-
sion (MCAo) on day 14. A second group (Gr.E/E) received
17b-estradiol capsules on day 0 and new 17b-estradiol
capsules on day 14. A third group (Gr.E/P) received 17b-
estradiol capsules on day 0, which were substituted with
placebo capsules on day 14. The last group (Gr.P/E)
received placebo capsules on day 0, which were substi-
tuted with 17b-estradiol capsules on day 14 (Figure 1).
Figure 1 Study flow-chart. All animals were ovariectomized day 0 of the experiment, and at the same time Gr.P/P and Gr.P/E received placebo
implants, while Gr.E/E and Gr.E/P received estrogen implants. Day 14 of the experiment, all animals underwent 60 minutes of MCAo. During the
anesthesia, blood samples were drawn and the implants were replaced with new ones. Gr.P/P and Gr.E/P received placebo implants, while Gr.E/E and
Gr.P/E received estrogen implants. On day 17 of the experiment, all animals were sacrificed, trunk blood collected and brains harvested for analysis.
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The wash-out period was omitted in the current
experiment because it has been shown to have no effect
on the levels of estrogens induced by the administration
regimen [23].
Production of silastic capsules
The silastic capsules consisted of thirty mm segments of
silastic laboratory tubing (inner/outer diameter: 1.575/
3.175 mm, Dow Corning, VWR International, Buffalo
Grove, IL, USA) filled with sesame oil (placebo) or a solu-
tion of 180 μg 17b-estradiol/mL sesame oil. Five mm
pieces of wooden applicator sticks (birch, length: 15 cm,
diameter: 2 mm, SelefaTrade AB, Spånga, Sweden) were
cut using a fine tooth saw and used to seal the silastic
tubing, resulting in an oil-17b-estradiol-filled column 20
mm in length. The capsules were stored overnight in a
vial containing sesame oil with the same concentration of
17b-estradiol as inside the capsules. Before implantation
the capsules were carefully wiped. A 0.5 cm incision was
made in the loose skin of the rat’s neck, and a pocket was
bluntly dissected caudally, in which the silastic capsule
was gently installed using forceps. The incision was sub-
sequently closed by a suture. This 17b-estradiol adminis-
tration regimen produces hormone serum levels that are
within the physiological range and significantly different
to ovariectomized controls for at least four weeks
(Figure 2) [23].
Figure 2 Serum estradiol concentrations depends on administration mode. The three most commonly-used methods for administrating
17b-estradiol to rats were tested in a previous study [23]: slow-release pellets (0.25 mg 60 day-release pellets, 0.10 mg 90 day-release pellets)
and silastic capsules (silastic laboratory tubing, inner/outer diameter: 1.575/3.175 mm, filled with 20 mm columns of 180 μg 17b-estradiol/mL
sesame oil). Blood samples were obtained at days 2, 7, 14, 21, 28, 35 and 42 after administration, and hormone levels were analyzed. As can be
observed in the graph, silastic capsules produced 17b-estradiol concentrations that were within the physiological range for at least 4 weeks,
while the pellets resulted in early supraphysiological peaks followed by a substantial decrease.
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Middle cerebral artery occlusion
Fourteen days after ovariectomy and silastic capsule
implantation all animals underwent MCAo according to
the following procedure. Anesthesia was induced by 4.2%
isoflurane in a mixture (30%/70%) of oxygen/nitrous oxide
in an induction chamber. A soft endotracheal tube was
used for controlled ventilation (Zoovent, CWC600AP,
ULV Ltd., UK) using 1.2-1.4% isoflurane in a mixture
(30%/70%) of oxygen/nitrous oxide. The tidal volume and
ventilation frequency were carefully regulated using on
site monitoring of blood gases and acid/base status (AVL,
OPTI 1 Medical Nordic AB, Stockholm, Sweden). The
rats were placed with their left side up on a thermostatic
heating pad (Harvard Homeothermic Blanket System,
Edenbridge, UK) to maintain the core/rectum temperature
at 37.0 ± 0.5°C. The left femoral artery was cannulated
using a soft catheter (Micro-renathane® tubing, MRE-025
Braintree Scientific Inc., MA) primed with saline contain-
ing heparin (100 IU/mL, Lovens, Malmö, Sweden) for
registration of blood pressure (Blood Pressure Transducer,
56360, Stoelting, IL, USA) and pulse (Acq- Knowledge
software, BioPac system, Goleta, California, USA). Using
an operating microscope (Zeiss Opmi 6-H West Ger-
many), the left MCA was exposed transcranially [25]
removing part of the zygomatic bone but keeping the tem-
poral muscle and the facial and mandibular nerves. The
MCA was temporarily occluded during 60 min with a
microclip between the rhinocortical branch and the lenti-
culostriate artery [26].
Measuring the size of the ischemic brain lesions
On day 17 of the experiment, three days after MCAo, the
rats were anesthetized by pure carbon dioxide and sacri-
ficed by means of a rat guillotine. The brain was carefully
dissected out and cooled in +4°C saline. Two millimeter
thick coronary slices of the brain were cut out with razor
blades directed by a rat brain matrix (RBM-4000, ASI
Instrument Inc., USA) at bregma and 2, 4, 6, 8 mm pos-
terior and 2 and 4 mm anterior to bregma. The slices
were freed from the dura mater and soaked for 10 min in
a solution of 2% 2,3,5-triphenyltetrazolium hydrochloride
(TTC) in 0.1 mol/L PBS (pH 7.4) in a small Petri dish,
maintained at 37°C in a heater. Gentle stirring of the
slices was used to ensure even exposure of the surfaces
to staining. Excess TTC was then drained, and the slices
were scanned (ScanJet 2c, Hewlett-Packard). The size of
brain lesion was measured using SigmaScan Pro version
5 (SPSS Inc.) using an automatic threshold of 40% in the
green spectrum in a similar manner as described by
Bederson et al. and Goldlust et al. [27,28].
Blood samples
Blood samples for 17b-estradiol analysis was obtained by
venipuncture of the hind limb into serum tubes
(Vacuette® Serum Tubes, Hettich Labinstrument AB, Sol-
lentuna, Sweden) during MCAo anesthesia in all animals
day 14 of the experiment. Also, five of the animals in Gr.
E/E and eight of the animals in Gr.E/P had blood samples
taken day 16 of the experiment. Only 700 μL of blood
was withdrawn to minimize animal stress. Day 17 of the
experiment, animals were sacrificed and trunk blood col-
lected from all groups for 17b-estradiol analysis.
17b-estradiol radioimmunoassay
Serum levels of 17b-estradiol were analyzed using an 125I
radioimmunoassay kit (17b-estradiol double antibody,
KE2D, Siemens Healthcare Diagnostics Inc., Tarrytown,
NY, USA), which has previously been tested in rat sera
against other radioimmunoassays [29], and measured for
300 seconds in a gamma counter (Gamma Master 1277;
Wallac-Pharmacia, Turku, Finland). This method has a
lowest detectable concentration of 1.4 pg/mL and intra-
and interassay coefficients of variation of 4-13% and 3.5-
5.5%, respectively, depending on the concentration. All
samples in the study were analyzed in one single run.
Two standard curves were analyzed and all samples were
read against their closest standard curve. A volume of
100 μL of serum was used for each tube in standard
curves and samples. Standards and samples were ana-
lyzed in duplicate.
Four samples from a previous experiment including
cycling female rats [23] were analyzed in the same batch
to allow standardizing factorization of the values.
Protocol violations
Excluded animals
One rat in Gr.E/P was excluded because of technical
problems during surgery.
Excluded test results
All scanned brain slice image from two animals, one
each in Gr.P/E and Gr.E/P, and one scanned brain slice
image from one animal in Gr.E/E was lost in the analy-
sis process.
Measured concentrations of 17b-estradiol in two
blood samples from Gr.P/E and one blood sample from
Gr.E/E were excluded due to technical problems.
Statistics
The mean and standard error of the mean are used to
describe central tendency and variation throughout the
article. Size of ischemic brain lesions and 17b-estradiol
concentrations were analyzed with Kruskal-Wallis non-
parametric one-way analysis of variance and multiple
comparisons [30]. Differences in ischemic lesion sizes
between rats with and without the extra sampling occa-
sion in Gr.E/E and Gr.E/P were analyzed by means of
Mann-Whitey’s test, using the same computer program
as above. Differences with p-values < 0.05 were
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considered significant. The ischemic lesions are pre-
sented as percent of the total slice area.
Results
Impact of 17b-estradiol on size of ischemic brain lesion
The overall mean ischemic lesion of all slices were sig-
nificantly smaller in Gr.E/E (3.85 ± 0.70%) than in Gr.P/
P (7.15 ± 0.27%; p = 0.015). There were no significant
differences between Gr.P/P and the two groups Gr.E/P
and Gr.P/E, neither in combined mean ischemic lesion
area nor in any specific slice. The lesions in Gr.P/E
(10.02 ± 1.23%) were significantly larger than in Gr.E/E
and Gr.E/P (5.41 ± 0.95%; p < 0.001 and p = 0.009
respectively; Figure 3).
The mean lesion sizes were largest in the bregma
position (10.61 ± 2.49% to 20.58 ± 2.61%) and smallest
in bregma -8 mm position (0.0 to 0.32 ± 0.30%) in all
groups (Figure 4).
Physiologic parameters
The blood gases and blood pressures presented in Table
1 were registered immediately prior to the MCAo.
Serum levels of 17b-estradiol
On the day for MCAo (day 14) Gr.E/E and Gr.E/P had
significantly higher concentrations of serum 17b-estra-
diol than had Gr.P/P and Gr.P/E, as expected from the
preceding hormone treatments (all p-values < 0.05). Day
17, the last day of the experiment, the 17b-estradiol
concentrations in Gr.E/E were significantly higher than
in Gr.P/P (p < 0.0001) and in Gr.E/P (p = 0.024), and the
levels in Gr.P/E were significantly higher than in Gr.P/P
(p = 0.0039), as expected from the second round of hor-
mone treatments. However, the concentrations in Gr.P/E
were not significantly higher than in Gr.E/P. Serum 17b-
estradiol concentrations are presented in Table 2.
Possible effect of venipuncture on the size of the
ischemic lesion
The mean lesion area of the thirteen rats in Gr.E/E and
Gr.E/P that underwent an extra venipuncture on day 16
did not differ from the other rats in these groups (4.71
± 0.57% versus 4.34 ± 0.50%; p = 0.38).
Discussion
17b-estradiol protects against ischemic brain damage
from transient MCAo in female Sprague Dawley rats
when administered to provide physiological serum con-
centrations using silastic capsules both before and after
MCAo. No significant neuroprotection was found when
the 17b-estradiol was administered only during the two
weeks before or the three days immediately after MCAo.
The main purpose of the current experiment was
complementing an earlier study from our lab, using a
different method for 17b-estradiol administration, and
administering 17b-estradiol only before or after the
ischemic episode. Silastic capsules were used in the pre-
sent study instead of slow-release pellets from the
Figure 3 Total ischemic brain lesion. The mean ischemic lesion area calculated from all slices in each experimental group. Gr.P/P had
significantly larger lesions than Gr.E/E (p = 0.015).
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company IRA in the previous study (Table 3) [21]. Since
neuroprotection of 17b-estradiol was found in the cur-
rent study, while the opposite was found in the previous
experiment, the choice of administration method seems
to have a crucial effect on the results. Importantly, this
effect is not confined to producing different degrees of
neuroprotection, but the slow-release pellets actually
cause neurodamage instead of neuroprotection. This is
in concordance with a previous review comparing meth-
ods of studies reporting neuroprotection versus neuro-
damage of estrogen, showing that 17b-estradiol has only
been reported to be neurodamaging when slow-release
pellets from IRA have been used [22].
The reasons for discrepancies in results from the
silastic capsule and pellet method of administration of
17b-estradiol are probably the markedly different serum
concentration profiles produced (Figure 2). In previous
experiments in our lab we have shown that the pellets
result in extreme, supraphysiological levels for several
days or weeks, followed by a substantial decrease, while
silastic capsules produces serum levels that are,
although steadily decreasing, within the physiological
range for at least four weeks [23,31]. In the light of
these administration method studies it seems reasonable
to conclude that the early, prolonged, supraphysiological
peak of the pellets in the context of cerebral ischemia
exerts detrimental effects on the brain.
The time aspect of estrogens’ effects on cerebral ische-
mia, investigated in the current study, has been
addressed in a few previous studies. In 1997, Simpkins
et al. compared infarct volumes when 17b-estradiol had
been intravenously administered 24 h before, 40 min
and 90 min after ischemic damage respectively and
found a protective effect at all three time points [10]. In
2000, Yang et al. administered 17b-estradiol through
intravenous injections and silastic capsules (filled with
crystalloid hormone, differing from the oil-solution
adopted in the current experiment) at 0.5, 1, 2, 3 and 4
hours after onset of ischemia finding less neuroprotec-
tion with later administration [32]. Saleh et al. con-
ducted two experiments in 2001 where the time aspect
Figure 4 Ischemic lesion in individual slices. Mean areas of ischemic lesions in individual slices are presented. The lesions were largest at
bregma and smallest in bregma -8 mm in all experimental groups.
Table 1 Physiological parameters in rats subjected to
transient MCA occlusion
Group n p02 (kPa) pCO2 (kPa) pH Systolic blood
pressure (mm Hg)
Gr.P/P 12 12.1 ± 0.9 5.1 ± 0.3 7.52 ± 0.04 100 ± 4
Gr.E/E 12 14.7 ± 1.3 5.2 ± 0.2 7.49 ± 0.01 113 ± 3
Gr.E/P 11 16.1 ± 1.3 5.0 ± 0.1 7.48 ± 0.01 110 ± 3
Gr.P/E 12 12.8 ± 2.4 5.5 ± 0.4 7.49 ± 0.03 105 ± 9
Table 2 Concentrations of 17b-estradiol
(mean ± SEM pg/mL)
Group Day 14 (MCAo) Day 16 Day 17 (sacrifice)
Gr.P/P 1.5 ± 0.7 Not measured 2.5 ± 1.8
Gr.E/E 10.1 ± 5.4 35.6 ± 8.5 32.4 ± 8.5
Gr.E/P 12.8 ± 4.7 8.0 ± 4.6 7.7 ± 2.1
Gr.P/E 1.6 ± 1.0 Not measured 11.8 ± 3.5
Strom et al. BMC Neuroscience 2010, 11:39
http://www.biomedcentral.com/1471-2202/11/39
Page 6 of 9
of estrogens effect on cerebral ischemia was investigated.
In one, subcutaneous injections of 17b-estradiol were
administered at 30 min before ischemia, at the onset of
ischemia and at 30 min after the onset of ischemia
respectively. It was found that administration 30 min
before ischemia produced the most substantial neuro-
protection, and that administration 30 min after ische-
mia did not significantly influence the infarct size [12].
In the other, the hormone was administered by intra-
ventricular infusion at 30 and 10 min before ischemia
respectively, with the result that more protection was
obtained from the earlier time point [33]. In 2007, Liu
et al. administered subcutaneous injections of 17b-estra-
diol at 30 min and at 6 hours after onset of ischemia
respectively, only finding neuroprotection from the first
time of injection if all rats were counted [34]. The nar-
row time span for hormone administration, differing at
most 25.5 h [10], and the administration methods
adopted in all of these previous studies contrast strongly
with the current study, which makes precise compari-
sons difficult. However, our present observations suggest
that administering estrogens by means of slow-release
silastic tubes at the time of ischemia lacks the protective
properties of a long-term estrogen treatment, which is
in contrasts to earlier results [10,32,34]. Thus, the cur-
rent results indicate that administering 17b-estradiol
only at the time of stroke by silastic capsules is ineffec-
tive, and that the protective potential of 17b-estradiol is
facilitated by prophylactic long-term administration.
However, the impact of estrogens during the develop-
ment of the ischemic damage is suggested by the fact
that no significant protection was observed in Gr.E/P,
receiving only estrogen pretreatment, while protection is
seen when at-stroke estrogens are added to this regime,
as in Gr.E/E.
Similar reasoning can be applied when considering the
results from Gr.E/P. Although this regime seems to lack
protective properties by itself, the partial neuroprotec-
tive of estrogen pretreatment is suggested by the lack of
protection in Gr.P/E in comparison to Gr.E/E. To our
knowledge, no study investigating the effect of 17b-
estradiol pretreatment, interrupted at the time of
ischemic damage, has been previously reported.
The 17b-estradiol concentrations in Gr.E/P and Gr.P/E
did not differ significantly on the last day of the experi-
ment. Because the half-life of 17b-estradiol in the blood
is measured in minutes, the comparatively small decrease
in hormone levels in Gr.E/P was unexpected. A possible
reason could be that although the hormone-containing
capsules had been replaced with placebo capsules, some
of the hormone could still have been left in the subcutis.
This hypothesis is supported by the lack of hormone
level decrease between days 14 to 17 in Gr.E/P.
Possible mechanisms
The elucidation of the mechanisms behind estrogens
effects on cerebral ischemia is of fundamental impor-
tance for the possibility of directly affecting the patholo-
gical process. Many mechanisms have been suggested to
be involved in the protective effects of 17b-estradiol in
the brain, being mediated by intracellular receptors,
membrane receptors and by direct chemical interactions
including antioxidant effects [35]. Interestingly, the anti-
oxidant effects of estrogens (phenolic scavenging of lipid
peroxyl radicals) may prevail at physiological concentra-
tions whereas redox-cycling at higher estrogen concen-
trations may lead to increased radical generation and
damage [36,37]. Estrogens may also protect against neu-
rodamage by antithrombogenic actions through effects
on smooth vascular muscle and endothelium, systemic
effects reducing total cholesterol and LDL concentra-
tions, and through effects on hepatic expression of
genes for several coagulation and fibrinolytic proteins.
Also, estrogens have direct effects on neurons by
Table 3 Methodological comparison of previous and present study
Methodological parameter Theodorsson & Theodorsson 2005 Present study
Estrogen administration mode Pellets from Innovative Research of America Home-made silastic capsules
Length of estrogen treatment 2 weeks
Type of estrogen 17b-estradiol
Method for induction of ischemic lesions MCAo by microclip, reperfusion after 60 min
Length of time between ischemia and damage evaluation 72 hours
Type of outcome measure TTC-staining and infarct size measurement
Rat sex Female
Rat strain Sprague-Dawley
Rat age 3 months
Rat diseases None
Miscellaneous Same laboratory, surgeon and technical equipment used in both studies
Effect of 17b-estradiol on cerebral ischemia Neurodamage (p < 0.001) Neuroprotection (p = 0.015)
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increasing transcription of antiapoptotic genes, decreas-
ing transcription of apoptotic genes, reducing mitochon-
drial release of Cytochrome C, interacting with
neurotrophins, and have anti-inflammatory effects
through attenuation of TNF-a (reviewed in [38,39]).
Damaging effects on the nervous system by estrogens
have been suggested to result from the formation of free
radicals [40] or from increased excitotoxicity [41] by up-
regulating glutamate NMDA receptors [42], inducing
seizure activity [43] and decreasing glutamate uptake by
astrocytes [44]. Thus, it seems reasonable that all these
mechanisms, differing in both route of exertion and
individual dose-response relations, together could create
a highly complex, e.g. biphasic, dose-response relation.
Conclusions
The hypothesis that the mode of estrogen administra-
tion dictates the hormone’s effect on ischemic damage
by producing specific hormone release profiles is corro-
borated by the present study. It is important to realize
that this is not merely a methodological question con-
cerning rat models, but suggests a fundamental property
of estrogens’ actions in the nervous system. Thus, it
does not only have relevance for the design of future
animal studies; it also has a bearing on the debate on
peri-menopausal hormone replacement therapy. Perhaps
altered administration regimens resulting in lower
plasma concentrations may reduce the hazardous effects
and even have favorable effects, while preserving the
relief of peri-menopausal symptoms?
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